These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7354946

  • 41. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I, Summa JD.
    Med Klin; 1980 Nov 07; 75(23):823-5. PubMed ID: 7442597
    [Abstract] [Full Text] [Related]

  • 42. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
    Reuter W.
    Z Alternsforsch; 1982 Nov 07; 37(6):409-16. PubMed ID: 7164480
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A, Ljachnicky N.
    Schweiz Rundsch Med Prax; 1988 Jul 05; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract] [Full Text] [Related]

  • 46. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Slawiński M, Czarnecka H.
    Fortschr Med; 1989 Jul 10; 107(20):450-2. PubMed ID: 2767596
    [Abstract] [Full Text] [Related]

  • 47. [Modification of pathologic fatty acid patterns in old age by combined clofibrinic and nicotinic acid treatment].
    Reuter W.
    Z Alternsforsch; 1983 Jul 10; 38(5):383-8. PubMed ID: 6659567
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J, Samochowiec L, Gawrońska-Szklarz B, Kwapiszewski W, Borkowski L.
    Acta Pol Pharm; 1985 Jul 10; 42(3):305-8. PubMed ID: 4096253
    [No Abstract] [Full Text] [Related]

  • 50. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H, Rothley D, Ewert M, Nachev P.
    Arzneimittelforschung; 1980 Jul 10; 30(6):984-8. PubMed ID: 7191278
    [Abstract] [Full Text] [Related]

  • 51. [Lipid lowering improved? Therapeutic progress by using biological mechanisms].
    Udelhoven P.
    Med Welt; 1982 Sep 10; 33(36):3. PubMed ID: 7132677
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981 Sep 10; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 54. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
    Bolzano K, Krempler F, Haslauer F.
    Arzneimittelforschung; 1979 Sep 10; 29(10):1621-4. PubMed ID: 583231
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B, Einarsson K, Leijd B.
    Eur J Clin Invest; 1984 Feb 10; 14(1):73-8. PubMed ID: 6421601
    [Abstract] [Full Text] [Related]

  • 57. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP, Kurlat MI, Neuman J.
    Curr Med Res Opin; 1983 Feb 10; 8(5):358-67. PubMed ID: 6839800
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
    Mertz DP.
    Fortschr Med; 1980 Dec 04; 98(45):1761-6. PubMed ID: 7461569
    [Abstract] [Full Text] [Related]

  • 60. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
    Colombo L, Monarca A, Goldberg D, Zanetta R.
    Clin Ter; 1979 Oct 31; 91(2):155-71. PubMed ID: 540479
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.